Galacto- oligosaccharides

Parents naturally want to offer their children the best available nutrition in order to help them grow strong and healthy. Oligosaccharides are a vitally important component of human milk1, not present in cow’s milk1. In order to reach the desired levels of oligosaccharides in infant formula, FrieslandCampina Ingredients developed Vivinal® GOS.

Benefits

Product Range

FrieslandCampina Ingredients offers four different products containing Vivinal® GOS, three products are in liquid form (syrup) and one product is in powder form. The composition of the galacto-oligosaccharides in Vivinal® GOS varies in chain length and type of linkage between the monomer units.

* on dry matter, ** on product

Moisture (%) Galacto-oligosaccharides (%) Mono and disaccharides (%) Protein (%)
Vivinal® GOS Syrup - 59* 41* <0,1*
Vivinal® GOS Syrup Organic - 59* 41* <0,1*
Vivinal® GOS Easy Drying Syrup - 72* 28* <0,1*
Vivinal® GOS Powder 2 69** 28** 0,3**

What is Vivinal® GOS?

Vivinal® GOS contains galacto-oligosaccharides (GOS). GOS are non-digestible carbohydrates, which are almost not broken down by human digestive enzymes. Because of this, they reach the intestine nearly completely intact, where they are then available for the present microflora 2,3.

In the colon they are fermented by, and stimulate the growth of, Bifidobacteria 4,5 . This may result in a broad range of positive health effects 6,7,8.

How is it made?

Vivinal® GOS is produced by enzymatic conversion of lactose present in the whey fraction of cow’s milk by use of β-galactosidases. It consists of galactose chains, starting with glucose, with a degree of polymerization (DP) between 2 and 10.

 

Vivinal® GOS is the most widely used prebiotic* ingredient for infant nutrition in the world. It contains non-digestible galacto-oligosaccharides. Several studies show that galactooligosaccharides can have following potential benefits for consumers:

Stimulation of growth of bifidogenic bacteria

The galacto-oligosaccharides (GOS) present in Vivinal® GOS are non-digestible food components which can be fermented in the large intestine. Bifidobacteria and Lactobacillia are easily able to ferment GOS resulting in stimulation of the growth and/or activity of these bacteria in the colon 9.

Vivinal® GOS can play an important role in the colonization of the new-born microbiota by promoting the growth of bifidogenic bacteria 9-12.

A substantial number of studies with formula-fed infants have shown that infant formula enriched with Vivinal® GOS resulted in a significant increase in Bifidobacteria, in comparison to infants receiving a standard formula without GOS 10-12.  Furthermore, similar studies investigating the effect of mixtures of oligosaccharides, among which GOS, on the microflora found comparable effects 13-21.

Contribution to softer and more frequent stools

Stools from formula-fed infants are known to be harder compared to the stools of breastfed infants 35 .

Several studies in infants showed that consumption of infant formula containing GOS (either alone or in a prebiotic mixture) results in softer stools and/or a higher frequency of stools 10,12,14,17,21,36-40.

These results indicate that addition of GOS to infant nutrition may contribute to healthy digestive function in infants.

Contribution to natural defences

Infants are born with an immature immune system, which is biased towards a Th2 response. This increases the risk of an infant developing an allergic disease, such as atopic dermatitis or a food allergy. There are indications that the composition of the intestinal microflora plays an important role in postnatal immune system development 23.

Several studies have evaluated the effect of oligosaccharides, among which GOS, on the incidence of infections in infants. These studies found that the overall number of eczema, infections, respiratory tract infections, intestinal infections, fever episodes and antibiotic prescription were significantly lower in the group fed oligosaccharides 24-28.

In infants at high risk of developing atopic disease, supplementation of infant formula with GOS and lcFOS during the first six months of life was shown to reduce the incidence of atopic dermatitis 27. This effect persisted at two-year and five-year follow up 25,26. These results suggest that early life intervention with oligosaccharides has a prolonged protective effect against development of allergic disease.

Two studies in infants have shown that supplementation of infant formula with GOS and lcFOS increases faecal sIgA to levels that are comparable to those found in breast fed infants 34, 46. Next to that, in vitro studies have shown that GOS can reduce pathogen adhesion in the gut 29,30. Two studies with infants showed a reduction of infections gastrointestinal and respiratory when their infant formula was supplemented with GOS and lcFOS 24, 25.

Vivinal® GOS can act via several routes:

  • Indirectly; by inhibiting the binding and/or survival of Escherichia ColiClostridia and Cholera toxin in the body, thereby reducing the risk of infections 29, 30
  • Indirectly; by the production of antimicrobial substances (products of GOS fermentation, like SCFA) which reduce the proliferation of pathogens 31, 32
  • Directly through interaction with immune cells. For example, commercial available oligosaccharides, among which GOS, have been shown to increase the number of NK cells, to increase the levels of serum IgA, and to reduce the plasma levels of IgE and IgG 28, 33, 34.

Improvement of mineral absorption

Adequate bioavailability of minerals is critical for bone development. The mineral calcium (Ca) for example is important for bone mineralization 41. It is known that 75% of the calcium in human milk is absorbed by infants, compared to 20% of the calcium in milk-based infant formulas 41.

GOS has been shown to increase the calcium absorption in both animals and humans 42-45. There are further indications that Vivinal® GOS can also improve the absorption of magnesium 42.

A clinical trial investigating the effect of Vivinal® GOS on calcium absorption in children aged 9-13 years, found that consumption of 5 and 10 g GOS per day during 3 weeks increased calcium absorption 35.

 

Vivinal® GOS from FrieslandCampina Ingredients has more than 20 years of safe use and is trusted by the major producers of infant nutrition. Vivinal® GOS is an ideal oligosaccharide ingredient for use in the production of infant formula (IF), follow-on formula (FOF) and growing-up milk (GUM).We are proud that Vivinal® GOS is the most widely used oligosaccharide ingredient in infant nutrition throughout the world. Since its introduction in 2000, more than 160 million babies worldwide have been nourished with infant formula containing Vivinal® GOS.

Watch our video for more information.

* The scientific definition of a prebiotic is: nondigestible food ingredients that beneficially affect the host by selectively stimulating the growth and/or activity of one or a limited number of bacteria in the colon

Source: Gibson, G.R. and Roberfroid, M.B., “Dietary Modulation of  the Human Colonic Microbiota: Introducing the Concept of  Prebiotics,” Journal of Nutrition, 125: 1401-1412 (1995).

Whether you can use the claim prebiotic on your products depends on local legislation.

References

  1. Bode L. Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology 2012:22(9):1147-1162
  2. Boehm G, Jelinek J, et al. Prebiotics in infant formulas. J Clin Gastroenterol 2004;38(6 Suppl):S76-S79.
  3. Barile D, Rastall RA. Human milk and related oligosaccharides as prebiotics. Curr Opin Biotechnol 2013;24(2):214-219.
  4. Rijnierse A, Jeurink PV, et al. Food-derived oligosaccharides exhibit pharmaceutical properties. Eur J Pharmacol 2011:668 Suppl 1:S117-23.
  5. Maathuis A.J.H., Heuvel van den E.G., et al. Galacto-oligosaccharides have prebiotic activity in a dynamic in vitro colon model using a 13C-labeling technique. J. Nutr. 2012:142(7):1205-1212.
  6. Gibson GR. Dietary modulation of the human gut microflora using prebiotics. Br J Nutr 1998;80(4):S209-S212.
  7. Macfarlane GT, Steed H, et al. Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics. J Appl Microbiol 2008;104(2):305-344.
  8. Roberfroid MB. Prebiotics and probiotics: are they functional foods? Am J Clin Nutr 2000;71(6 Suppl):1682S-1687S.
  9. Maathuis A.J.H., Heuvel van den E.G., et al. Galacto-oligosaccharides have prebiotic activity in a dynamic in vitro colon model using a 13C-labeling technique. J. Nutr. 2012:142(7):1205-1212.
  10. Ben XM, Li J, et al. Low level of galacto-oligosaccharide in infant formula stimulates growth of intestinal Bifidobacteria and Lactobacilli. World J Gastroenterol 2008;14(42):6564-6568.
  11. Fanaro S, Marten B, et al. Galacto-oligosaccharides are bifidogenic and safe at weaning: a double-blind randomized multicenter study. J Pediatr Gastroenterol Nutr 2009;48(1):82-88.
  12. Ben XM, Zhou XY, et al. Supplementation of milk formula with galacto-oligosaccharides improves intestinal micro-flora and fermentation in term infants. Chin Med J (Engl ) 2004;117(6):927-931.
  13. Schmelze H, Wirth S, et al. Randomized double-blind study of the nutritional efficacy and bifidogenicity of a new infant formula containing partially hydrolyzed protein, a high beta-palmitic acid level, and nondigestible oligosaccharides. J Pediatr Gastroenterol Nutr 2003;36(3):343-351.
  14. Costalos C, Kapiki A, et al. The effect of a prebiotic supplemented formula on growth and stool microbiology of term infants. Early Hum Dev 2008;84(1):45-49.
  15. Scholtens PA, Alles MS, et al. Bifidogenic effects of solid weaning foods with added prebiotic oligosaccharides: a randomised controlled clinical trial. J Pediatr Gastroenterol Nutr 2006;42(5):553-559.
  16. Moro GE, Mosca F, et al. Effects of a new mixture of prebiotics on faecal flora and stools in term infants. Acta Paediatr Supple 2003;91(441):77-79.
  17. Moro G, Minoli I, et al. Dosage-related bifidogenic effects of galacto- and fructooligosacchardies in formula-fed infants. J Pediatr Gastroenterol Nutr 2002;34(3):291-295.
  18. Knol J, Scholtens P, et al. Colon microflora in infants fed formula with galacto- and fructo-oligosaccharides: more like breast-fed infants. J Pediatr Gastroenterol Nutr 2005;40(1):36-42.
  19. Haarman M, Knol J. Quantitative real-time PCR analysis of fecal Lactobacillus species in infants receiving a prebiotic infant formula. Appl Envrion Microbiol 2006;72(4):2359-2365.
  20. Desci T, Arato A, et al. Randomised placebo controlled double blind study on the effect of prebiotic oligosaccharides on intestinal flora in healthy infants. Orv Hetil 2005;146(48):2445-2450.
  21. Boehm G, Lidestri M, et al. Supplementation of a bovine milk formula with an oligosaccharide mixture increases counts of faecal bifidobacteria in preterm infants. Arch Dis Child Fetal Neonatal Ed 2002;86(3):F178-F181.
  22. Wallace TC, Guarner F, et al. Human gut microbiota and its relationship to health and disease. Nutrition Reviews 2011:69(7):392-403.
  23. Björkstén B, Sepp E, et al. Allergy Development and the intestinal microflora during the first year of life. Journal of allergy and Clinical Immunology2001;108(4):516-520.
  24. Bruzzese E, Volpicelli M, et al. A formula containing galacto- and fructooligosaccharides prevents intestinal and extra-intestinal infections: an observational study. Clin Nutr 2009;28(2):156-161.
  25. Arslanoglu S, Moro GE, et al. Early dietary intervention with a mixture of prebiotic oligosaccharides reduces the incidence of allergic manifestations and infections during the first two years of life. J Nutr 2008;138(6):1091-1095.
  26. Arslanoglu S, Moro GE, et al. Early neutral prebiotic oligosaccharide supplementation reduces the incidence of some allergic manifestations in the first 5 years of life. J Bio Regul Homeost Agents 2012;26(3 Suppl):49-59.
  27. Moro G, Arslanoglu S, et al. A mixture of prebiotic oligosaccharides reduces the incidence of atopic dermatitis during the first six months of age. Arch Dis Child 2006;91(10):814-819.
  28. Van Hoffen E, Ruiter B, et al. A specific mixture of short-chain galactooligosaccharides and longchain fructooligosaccharides induces a beneficial immunoglobulin profile in infants at high risk for allergy. Allergy 2009;64:484-487.
  29. Shoaf K, Mulvey GL, et al. Prebiotic galactooligosaccharides reduce adherence of enteropathogenic Escherichia coli to tissue culture cells. Infect Immun 2006;74(12):6920-6928.
  30. Sinclair HR, de SJ, et al. Galactooligosaccharides (GOS) inhibit Vibrio cholerae toxin binding to its GM1 receptor. J Agric Food Chem 2009;57(8):3113-3119.
  31. Macfarlane GT, Steed H, et al. Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics. J Appl Microbiol 2008;104(2):305-344.
  32. Vos AP, M’Rabet L, et al. Immune-modulatory effects and potential working mechanisms of orally applied nondigestible carbohydrates. Crit Rev Immunol 2007;27(2):97-140.
  33. Gopalakrishnan A, Clinthorne JF, et al. Supplementation with Galacto-Oligosaccharides increases the percentage of NK cells and reduces colitis severity in Smad3-deficient mice. J Nutr 2012;142:1336-1342.
  34. Bakker-Zierikzee AM, Tol EA.Faecal SigA secretion in infants fed on pre-or probiotic infant formula. Pediatr Allergy Immunol 2006:17(2): 134-40.
  35. Quinlan PT, Lockton S, et al. The relationship between stool hardness and stool composition in breast- and formula-fed infants. J Pediatr Gastroenterol Nutr 1995;20(1):81-90.
  36. Ashley C, Johnston WH, et al. Growth and tolerance of infants fed formula supplemented with polydextrose (PDX) and/ or galactooligosaccharides (GOS): double-blind, randomized, controlled trial. Nutr J 2012;11(38).
  37. Sierra C, Bernal MJ, et al. Prebiotic effect during the first year of life in healthy infants fed formula containing GOS as the only prebiotic: a multicentre, randomised, double-blind and placebo-controlled trial. Eur J Nutr 2015;54:89-99
  38. Ribeiro T, Costa-Ribeiro H, et al. Stool pattern changes in toddlers consuming a follow-on formula supplemented with polydextrose and galactooligosaccharides. J Pediatr Gastroenterol Nutr 2012;54(2):288-290.
  39. Ziegler E, Vanderhoof JA, et al. Term infants fed formula supplemented with selected blend of prebiotics grow normally and have soft stools similar to those reported for breast-fed infants. Journal of Pediatric Gastroenterology and Nutrition 2007; 44:359-364.
  40. Veereman-Wauters G, Staelens S, et al. Physiological and bifidogenic effects of prebiotic supplements in infant formulae. J Pediatr Gastroenterol Nutr 2011;52(6):763-771.
  41. Baker SS, Cochran WJ, et al. American Academy of Pediatrics. Committee on Nutrition. Calcium requirements of infants, children, and adolescents. Pediatrics 1999;104(5 Pt 1):1152-1157.
  42. Weaver CM, Martin BR, et al. Galactooligosaccharides improve mineral absorption and bone properties in growing rats through gut fermentation. J Agric Food Chem 2011;59(12):6501-6510 .
  43. Whisner CM, Martin BR, et al. Galacto-oligosaccharides increase calcium absorption and gut bifidobacteria in young girls: a double-blind cross-over trial. Br J Nutr 2013;110(7):1292-1303.
  44. Chonan O, Watanuki M. Effect of galactooligosaccharides on calcium absorption in rats. J Nutr Sci Vitaminol (Tokyo) 1995;41(1):95-104.
  45. Chonan O, Watanuki M. The effect of 6′-galactooligosaccharides on bone mineralization of rats adapted to different levels of dietary calcium. Int J Vitam Nutr Res 1996;66(3):244-249.
  46. Scholtens PA, Alliet P, et al. Fecal secretory immunoglobulin A is increased in healthy infants who receive a formula with short-chain galacto-oligosaccharides and long-chain fructooligosaccharides.J Nutr 2008;138(6):1141-1147.
  47. Ladirat SE, Schoterman MHC, et al. Exploring the effects of galacto-oligosaccharides on the gut microbiota of healthy adults receiving amoxicillin treatment. Br J Nutr 2014; 112(4):536-46.
  48. Tamai S, Nakamura Y, et al. Effect of galactooligosaccharides intake on human fecal flora and metabolites. Oyo Toshitsu Kagaku 1994;41(3):343-348.
  49. Ito M, Kimura M, et al. Effects of transgalactosylated disaccharides on the human intestinal microflora and their metabolism. J Nutr Sci Vitaminol (Tokyo) 1993;39(3):279-288.

Get in touch

Contact our experts
Request a sample Subscribe to our newsletter